Erste Group downgraded Eli Lilly (LLY) to Hold from Buy. The company lowered its earnings forecast for 2025, says the firm, which expects the shares to trend sideways in the medium term.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly Stock (LLY) Grows Despite U.K. Warnings to Pregnant Women Over Weight Loss Jabs
- Mizuho medical devices/diagnostic analysts hold analyst/industry conference call
- Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins
- Eli Lilly’s (LLY) CFO to Participate in Goldman Sachs Health Conference
- Eli Lilly announces new Phase 1 data for LY4170156 at ASCO